I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data
PositiveFinancial Markets

I-Mab's stock has been reaffirmed as a 'Buy' by H.C. Wainwright following promising data on its cancer drug. This endorsement highlights the potential of I-Mab's treatment in the competitive oncology market, which could lead to increased investor confidence and support for the company's future growth. Positive clinical results not only boost the company's reputation but also enhance its prospects for successful partnerships and funding.
— Curated by the World Pulse Now AI Editorial System









